Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

NCT05192941 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1770

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Inclisiran Sodium
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals